Detalhe da pesquisa
1.
Ovarian and cervical cancer patient derived xenografts: The past, present, and future.
Gynecol Oncol
; 138(2): 486-91, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26026736
2.
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
Gynecol Oncol
; 134(2): 331-7, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24844596
3.
Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).
J Biol Chem
; 287(21): 17682-17692, 2012 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22433870
4.
The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.
Int J Mol Sci
; 14(4): 8213-27, 2013 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23591839
5.
Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Mol Cancer Res
; 16(5): 813-824, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29523763
6.
Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
Clin Cancer Res
; 23(21): 6529-6540, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28778862
7.
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
Oncotarget
; 5(16): 7065-80, 2014 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25216523
8.
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.
Oncotarget
; 5(18): 8750-64, 2014 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25209969
9.
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.
Obstet Gynecol
; 124(5): 881-885, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25437714
10.
Isolation and characterization of potential cancer stem cells from solid human tumors--potential applications.
Curr Protoc Pharmacol
; 63: 14.28.1-14.28.19, 2013 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24510756
11.
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
Clin Cancer Res
; 19(1): 170-82, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23147994
12.
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.
Clin Cancer Res
; 18(3): 869-81, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22142828
13.
Smoothened antagonists reverse taxane resistance in ovarian cancer.
Mol Cancer Ther
; 11(7): 1587-97, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22553355
14.
SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.
Mol Cancer Res
; 10(11): 1462-72, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22964433